tbuckley/cabot-search huggingface dataset:
THU0254 Risk factors for back pain in a cross sectional and in a one-year follow up study in nurses
Authors: M Brzosko, I Fiedorowicz-Fabrycy, J Fliciñski, H Przepiera-Bêdzak, K Prajs
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To find risk factors for back pain in retrospective study, one year follow-up study, recurrence and first episode of back pain in one year follow-up study in nurses. <h3>Methods</h3> The study was performed on 470 nurses of clinical hospital, 92,3% of nurses answered a questionnaire concerning information about low back pain. 358 (82,5%) have answered the questionnaire on the physical activities performed at work and 369 (85,0%) were examined. 87,9% of nurses who answered the first questionnaire have taken part in follow up study. The potential relationship of the investigated 47 variables like financial status, habits, physical activity or work conditions were assessed in multivariate logistic regression model and then the role of significant variables was counted as relative risk with 95% of confidence interval in univariate logistic regression model. For statistical evaluation of the data STATA 5.0 software was used. <h3>Results</h3> The multivariate logistic regression analysis did not show any common risk factor for back pain in cross sectional, one-year follow up study, for the first episode or for the reoccurrence of back pain in one-year follow up study. Cycling was a risk factor for back pain in both one year follow-up study and first episode (OR 1,3) and for recurrence of back pain (OR 1,9) and the same applied to work with arms elevated on the shoulder level longer than 1 min an hour. These two variables were the only significant risk factors (p &lt; 0,05) for the first episode of back pain in one-year follow up study. Spinal mobility ranges in different planes did not have any impact on first episode of back pain. Age, bringing up children, alcohol drinking, experiencing recurrent diarrheas, abdominal pain, discontentment with own job, limited lateral trunk flexion to the right, pushing heavy objects and both hands lifting weights were risk factors only for reoccurrence of back pain in a one-year follow up study. Bad assessment of the own health was a risk factor of back pain in cross sectional, one-year follow up study and especially for the reoccurrence of back pain in one-year follow up study. <h3>Conclusion</h3> There are different risk factors of back pain in retrospective study, one year follow-up study, recurrence and first episode of back pain in one year follow-up study in nurses.
Intrauterine Exposure to Biologics in Inflammatory Autoimmune Diseases: A Systematic Review
Authors: N. Ghalandari, R. J. E. M. Dolhain, J. M. W. Hazes, E. P. van Puijenbroek, M. Kapur, H. J. M. J. Crijns
Journal: Drugs (2020)

Inflammatory autoimmune diseases are chronic diseases that often affect women of childbearing age. Therefore, detailed knowledge of the safety profile of medications used for management of inflammatory autoimmune diseases during pregnancy is important. However, in many cases the potential harmful effects of medications (especially biologics) during pregnancy (and lactation) on mother and child have not been fully identified. Our aim was to update the data on the occurrence of miscarriages and (major) congenital malformations when using biologics during pregnancy based on newly published articles. Additionally, we selected several different secondary outcomes that may be of interest for clinicians, especially information on adverse events in the use of a specific biologic during pregnancy. A search was conducted from 1 January 2015 until 4 July 2019 in Embase.com, Medline Ovid, Web of Science, Cochrane CENTRAL, and Google Scholar with specific search terms for each database. Selection of publications was based on title/abstract and followed by full text (double blinded, two researchers). An overview was made based on outcomes of interest. References of the included publications were reviewed to include and minimize the missing publications. A total of 143 publications were included. The total number of cases ranged from nine for canakinumab to 4276 for infliximab. The rates of miscarriages and major congenital malformations did not show relevant differences from those rates in the general population. Despite limitations to our study, no major safety issues were reported and no trend could be identified in the reported malformations.
Cerebrolysin in the therapy of mild cognitive impairment and dementia due to Alzheimer's disease: 30 years of clinical use
Authors: Svetlana I. Gavrilova, Anton Alvarez
Journal: Medicinal Research Reviews (2020)

Abstract Alzheimer's disease (AD) is the most common neurocognitive disorder and a global health problem. The prevalence of AD is growing dramatically, especially in low‐ and middle‐income countries, and will reach 131.5 million cases worldwide by 2050. Therefore, developing a disease‐modifying therapy capable of delaying or even preventing the onset and progression of AD has become a world priority, and is an unmet need. The pathogenesis of AD, considered as the result of an imbalance between resilience and risk factors, begins many years before the typical clinical picture develops and involves multiple pathophysiological mechanisms. Since the pathophysiology of AD is multifactorial, it is not surprising that all attempts done to modify the disease course with drugs directed towards a single therapeutic target have been unsuccessful. Thus, combined modality therapy, using multiple drugs with a single mechanism of action or multi‐target drugs, appears as the most promising strategy for both effective AD therapy and prevention. Cerebrolysin, acting as a multitarget peptidergic drug with a neurotrophic mode of action, exerts long‐lasting therapeutic effects on AD that could reflect its potential utility for disease modification. Clinical trials demonstrated that Cerebrolysin is safe and efficacious in the treatment of AD, and may enhance and prolong the efficacy of cholinergic drugs, particularly in moderate to advanced AD patients. In this review, we summarize advances of therapeutic relevance in the pathogenesis and the biomarkers of AD, paying special attention to neurotrophic factors, and present results of preclinical and clinical investigations with Cerebrolysin in AD.
Peripheral CD4+ T cell subsets and antibody response in COVID-19 convalescent individuals
Authors: Fang Gong, Yaping Dai, Ting Zheng, Liang Cheng, Dan Zhao, Hao Wang, Min Liu, Hao Pei, Tengchuan Jin, Di Yu, Pengcheng Zhou
Journal: Journal of Clinical Investigation (2020)

BACKGROUND. Marked progress is achieved in understanding the physiopathology of coronavirus disease 2019 (COVID-19), which caused a global pandemic. However, the CD4+ T cell population critical for antibody response in COVID-19 is poorly understood.
Circulating tumor cells (CTC) in patients with metastatic castration-resistant prostate cancer (CRPC) receiving abiraterone acetate (AA) after failure of docetaxel-based chemotherapy
Authors: M. Fleisher, D. C. Danila, M. Leversha, D. Rathkopf, S. Slovin, A. Anand, M. Koscuiszka, C. Haqq, H. I. Scher
Journal: Journal of Clinical Oncology (2009)

5049 Background: Selecting targeted therapies and assessing outcome in patients (pts) with CRPC are significant unmet medical needs. A proportion of CRPC remain dependent on androgen receptor (AR) activation. AA inhibits CYP17 to decrease serum androgen to undetectable levels. Methods: AA (1000 mg QD oral) was studied in pts with metastatic CRPC who had progressed on docetaxel based chemotherapy. The primary endpoint was a &gt;50% decline in PSA from baseline. We monitored changes in CTC number with therapy, and performed FISH for AR in CTC as previously described. Results: At MSKCC, 54 pts were screened and 48 treated; 38 pts received prednisone from the start of treatment. The median (IQR) age was 70 yrs (63–79), PSA 99.9 ng/mL (36.4–343), and CTC were 17 (4–49) per 7.5 ml of blood at baseline. Prior systemic therapy included &gt; 3 hormonal therapies in 63%; while 71% received 1, 29% had 2 lines of chemotherapy. Metastatic sites were bone alone in 10 pts (21%), bone and lymph nodes in 21 (44%), 15 (31%) with visceral disease, 2 with soft tissue alone. Baseline CTC count was &gt; 5 in 35 pts, whereas 13 pts had &lt;5; CTC changes with treatment are presented in table below. Pts in Group A were treated on protocol for a median of 8.9 m, compared to 2.8 m in group B (P &lt;0.001). Among pts with baseline CTC &gt; 5, the CTC decline to &lt;5 was associated with a decline in PSA by &gt;50% (p&lt; 0.001). From 28 pts with FISH in CTC, 13 (47%) pts had AR amplification, 8 (29%) pts had copy number gain, and 5 (10%) pts had no evident AR copy number abnormalities; FISH failed in 2 pts. PSA declined &gt; 50% in 5 (38%) pts with AR amplification, 2 (25%) pts with gain, and 4 (80%) pts without AR abnormalities. Conclusions: Changes in CTC with treatment may represent valuable intermediary endpoints for clinical benefit. We are prospectively testing pre and post-therapy CTC, and separately AR FISH profiles and clinical outcomes in COU-AA-301, a phase III trial for CRPC patients who have received docetaxel based chemotherapy. [Table: see text] [Table: see text]
THU0141 The diagnostic value of rheumatoid factors and antibodies to cyclic citrullinated peptide (ccp) in early arthritis
Authors: LM Jansen, IE Van der Horst-Bruinsma, D Van Schaardenburg, RJ Van de Stadt, MH De Koning, BA Dijkmans
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> <h3>Objectives</h3> To study the diagnostic value of IgM-RF, IgA-RF, anti-CCP and combinations of these antibodies measured at baseline to discriminate rheumatoid arthritis (RA) from undifferentiated polyarthritis (UPA) in patients with recent onset arthritis. <h3>Methods</h3> Early arthritis patients with peripheral arthritis of 2 or more joints and less than 3 years of symptom duration were clinically diagnosed as RA or UPA by the rheumatologist during the first year. Excluded from the study were patients with bacterial, psoriatic, crystal-induced arthritis or spondylarthropathy. Optimal cut-off values for serum IgM-RF, IgA-RF and anti-CCP were deduced from Receiver Operating Characteristics (ROC) curves. <h3>Results</h3> 379 patients (69% female, median age 57 (17–86)) were included. 258 patients were clinically diagnosed as RA and 121 as UPA. The Table 1 shows optimal cut-off values for IgM-RF (IU/ml), IgA-RF (arbitrary units: AU/ml) and anti-CCP (AU/ml) with the matching specificity and sensitivity percentages. Both the IgM-RF &gt; 40 and anti-CCP &gt; 50 have a high specificity but the sensitivities are low. Because in many RA patients the occurrence of IgM-RF and anti-CCP antibodies are independent from each other, the best test criterion proved to be the combination of IgM-RF &gt; 40 or anti-CCP &gt; 50, with a sensitivity of 55.4% and a specificity of 96.7%. <h3>Conclusion</h3> The criterion IgM-RF &gt; 40 or anti-CCP &gt; 50 is able to predict the onset of RA with a high specificity and acceptable sensitivity. Anti-CCP testing provides additional information on which to base treatment decisions in early arthritis.
Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine
Authors: M. L. Disis, L. G. Salazar, A. Coveler, J. Waisman, D. Higgins, J. Childs, N. Bates, Y. Dang
Journal: Journal of Clinical Oncology (2009)

3000 Background: Adoptive T-cell therapy has shown promise in the treatment of advanced-stage melanoma. We have previously reported that expansion of HER2-specific T cells from peripheral blood mononuclear cells (PBMC) can be greatly facilitated by vaccine-priming. In this study, we evaluated the safety and clinical efficacy of infusion of HER2-specific T cells in patients with advanced HER2 overexpressing cancers. Methods: 10 patients with progressive HER2 + metastatic breast and ovarian cancer, not considered curable by conventional therapies, will be enrolled in this study. The patients must have been pre-immunized with a HER2-specific vaccine. Three escalating doses of T cells are given at 10-day intervals. Cyclophosphamide or denileukin diftitox is administrated before the first dose of T cells. Results: To date, 5 of 10 subjects have been enrolled. T cells were expanded with HER2-specific class II restricted peptides. After in vitro expansion cell products were &gt;95% CD3 + with an average of 35% CD4 + and 60% CD8 + T cells. The maximal doses infused were 1x10 9 -41x10 9 cells (median 10x10 9 ). Subjects tolerated the infusions well with the primary toxicity being related to the conditioning agent. Objective tumor regression has been observed in 2 of the 5 treated patients. One other patient has had stable disease after treatment. In patients with tumor regression, the magnitude of HER2-specific T cells in the infused product was 8-fold higher than that in patients without clinical responses. The total number of HER2-specific T cells infused was 43-fold higher in responding patients than in nonresponding patients. Moreover, HER2-specific CD4 + and CD8 + T cells persisted over a year and even augmented in magnitude post-infusion in responding patients. Conclusions: Adoptive transfer of autologous HER2 specific polyclonal T cells generated from PBMC after vaccine-priming is well tolerated and has shown evidence of some clinical efficacy in patients with advanced-stage HER2 + cancers. No significant financial relationships to disclose.
A double-blind randomized trial of pyridoxine versus placebo for the prevention of pegylated liposomal doxorubicin hydrochloride-related palmar-plantar erythrodysesthesia
Authors: V. E. Von Gruenigen, H. Frasure, N. Fusco, E. Eldermire, S. Eaton, S. Waggoner
Journal: Journal of Clinical Oncology (2009)

5594 Background: To compare the efficacy of pyridoxine versus placebo in the prevention of palmar-plantar erythrodysesthesia (PPE) and on quality of life (QOL) in patients treated with pegylated liposomal doxorubicin hydrochloride for ovarian, breast, or endometrial cancer. Methods: All patients received pegylated liposomal doxorubicin hydrochloride 40 mg/m2 IV q 4 weeks over 1 hour every 28 days for a maximum of 6 cycles. Patients received pyridoxine 100 mg (group A) by mouth or placebo (group B) twice daily. Nurses conducted standard PPE education for all patients. Patients with Grade 2 or 3 PPE that persisted despite dose reductions/delays were unblinded, and were given pyridoxine if taking placebo. Patients completed the Functional Assessment of Cancer Therapy (FACT) assessment tool. Analyses were conducted by group and comparisons were also made between patients who experienced grade 2/3 PPE versus grade 0/1. Chi-square or Fisher's exact test were used. Results: Thirty-four patients were enrolled with 18 randomized to group A and 16 to group B. Mean age was 64 years (SD=9.6; range 45–81 years). Five patients (group A, 3; group B, 2) were unevaluable (due to pegylated liposomal doxorubicin hydrochloride reaction during first chemotherapy cycle). Overall 15/29 (52%) patients had incidence of PPE (all grades), with 10/29 (34%) having grade 2/3 events (no grade 4 events observed). In group A, 8/15 (53%) patients had a PPE event and 7/14 (50%) in group B; p=0.857. For grade 2/3 events, there was no difference as 6/15 (40%) occurred in group A and 4/14 (29%) in group B; p=0.70. There were no differences in global or domain QOL scores between those patients with Grade 2/3 PPE versus Grade 0/1. Less than half [4/10 (40%)] of patients with Grade 2/3 PPE reported being bothered by side effects of pegylated liposomal doxorubicin hydrochloride treatment. Conclusions: As administered in this study, pyridoxine did not prevent PPE in patients treated with pegylated liposomal doxorubicin hydrochloride. Quality of life differences were not observed; however, not all patients with PPE reported being bothered by side effects of pegylated liposomal doxorubicin hydrochloride treatment. Pyridoxine is not indicated for prevention of PPE during chemotherapy. [Table: see text] [Table: see text]
Colitis cystica profunda mimicking mucinous adenocarcinoma of the rectum diagnosed by endoscopic submucosal dissection
Authors: Takashi Abe, Marina Hamamoto, Takayuki Nagai, Takehiko Nariyasu, Masato Hanzawa, Yasuhisa Hiroshima, Kazunari Murakami
Journal: Endoscopy (2020)

A 48-year-old man presented to our hospital with complaints of fresh rectal bleeding. He was intellectually disabled and often inserted his fingers into the anus after defecation. Laboratory investigations demonstrated lowered hemoglobin level (9.3 g/dL; normal range 13.5 – 17.5 g/dL). Colonoscopy showed a polypoid submucosal tumor-like elevated lesion with redness and rough surface, along with erosion in the lower rectum ([Fig. 1 a, b]). Endoscopic ultrasonography (EUS) showed hypoechoic and several anechoic cystic lesions in the submucosa, without invasion of the muscularis propria ([Fig. 1 c]). Magnetic resonance imaging (MRI) showed peripheral contrast-enhanced cystic lesions in the lower rectum. Regional lymphadenitis in the lower rectum was not seen on MRI ([Fig. 2]). Boring biopsy was suggestive of mucinous adenocarcinoma.
THU0076 Adenovirus mediated gene transfer of urokinase plasminogen inhibitor inhibits angiogenesis in experimental arthritis
Authors: C Jorgensen, F Apparailly, C Bouquet, V Millet, D Noel, P Yeh, J Sany
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Plasmin is essential for metalloproteases (MMP) activation, endothelial cell migration and degradation of the extracellular matrix. The process is common to neoangiogenesis and pannus formation, and 80% of synovial cells express urokinase plasminogen activator receptor (uPAR). <h3>Objectives</h3> We inhibited plasmin activation by expressing uPA/uPAR antagonist chimeric molecule (ATF-HSA) through adenoviral mediated gene transfer in experimental arthritis. <h3>Methods</h3> Overexpression of ATF-HSA was obtained by IV injection of 109 pfu of a non replicative E1 deleted type 5 adenoviral vector containing murine ATF gene linked to HSA gene under the control of a CMV promoter. Collagen-induced arthritis (CIA) was obtained by immunisation of DBA1 mice with bovine type II collagen in FCA. AdATF-HSA was injected IV on day 25 after immunisation. On day 44, X ray and Immuno-histology of paws were performed. The SCID/hu model was used to assess the effect of adenoviral mediated huATF gene transfer on human rheumatoid synovium angiogenesis. <h3>Results</h3> <h3>Conclusion</h3> The uPAR antagonist ATF-HSA is a new tool for gene therapy in arthritis. The preventive effect observed may be related to the decrease in angiogenesis rather than inhibition of extracellular matrix degradation.
The psychology of protecting the UK public against external threat: COVID-19 and the Blitz compared
Authors: Edgar Jones
Journal: The Lancet Psychiatry (2020)

The COVID-19 pandemic and the World War 2 aerial bombing campaign against the UK between 1939 and 1945 both exposed the civilian population to a sustained threat. Risk, whether from exposure to viral load or the density of the bombing, led to a range of protective measures and behavioural regulations being implemented. The V1 and V2 missiles used in summer and autumn, 1944, functioned as a second wave of bombing, arriving after people believed the danger had passed. Adherence to lockdown and a reluctance to return to work after the lifting of lockdown during the COVID-19 pandemic in the UK were mirrored in the preference for using home-based bomb shelters during the air raids. Heightened sensitivity to risk, or a so-called deep shelter mentality, did not materialise even during the second wave of bomb attacks and some deep bomb shelters were closed because of low occupancy. The most popular protective measures were those that reflected people's preferences, and not necessarily those that provided the greatest safety. As with the COVID-19 pandemic, the public drove government policy as much as they followed it.
OP0036 Molecular cloning and characterisation of autoantigen recognised by anti-wa antibodies in patients with systemic sclerosis
Authors: Y Shirai, T Nojima, M Hirakata, H Yamagata, K Miyachi, T Mimori
Journal: Annals of the Rheumatic Diseases (2001)

<h3>Background</h3> Anti-Wa antibodies were first reported in patients with systemic sclerosis (SSc) as autoantibodies reactive with a 48kDa transfer RNA-associated protein.<sup>1</sup> However, the nature of the Wa antigen has not been clarified so far. <h3>Objectives</h3> To identify and characterise the Wa antigen by molecular cloning using anti-Wa serum as a probe. <h3>Methods</h3> Molecular cloning of the target Wa antigen was performed using lambda gt11 cDNA library constructed from human liver mRNA and anti-Wa protoype serum as a probe. Bound antibodies were eluted from the fusion proteins of the isolated clones expressed in E.coli and were used for RNA-immunoprecipitation assay. The reactivity of fusion proteins prepared from lysogenic E.coli Y1089 carrying the recombinant phages were examined using five sera that were proved to have anti-Wa antibodies in double immunodiffusion assay. The cDNA inserts of the isolated clones were sequenced, and the detailed homologies of nucleotide and amino acid sequences were analysed through the BLAST server at NCBI DNA databank. Anti-Wa antibodies in sera from patients with various rheumatic diseases were detected by immunoblot analysis using the fusion protein from the positive clone. <h3>Results</h3> 10 positive clones were recognised by the probe serum. In RNA-immunoprecipitation, the affinity-purified antibodies from only one clone (termed Wa-1) immunoprecipitated transfer RNA from HeLa cell extracts. In immunoblot study, the Wa-1 fusion protein was recognised by all five sera that were proved to have anti-Wa antibodies. These data confirmed that the Wa-1 clone encoded for the Wa antigen. The nucleotide sequence and deduced amino acid sequence of the 0.7-kb insert cDNA of Wa-1 were completely identical with the C-terminal part of NEFA (named after DNA-binding domain, two EF-hands, Acidic amino acid rich region)/nucleobindin-2.<sup>2</sup> In immunoblots using the Wa-1 fusion protein, autoantibodies to Wa (NEFA/nucleobindin-2) were detected in 3 of 21 SSc (21%), one of 10 RA (10%) and one of 16 SLE sera (6%). However, neither RA nor SLE sera immunoprecipitated transfer RNA from HeLa cells, while all 3 SSc sera immunopricipitated transfer RNA, suggesting the diversity of autoepitopes among patient sera. <h3>Conclusion</h3> These results demonstrated that the autoantigen recognised by anti-Wa antibodies were proved to be identical with NEFA/nucleobindin-2. <h3>References</h3> Miyachi K, <i>et al</i>. J Rheumatol. 1991;18:373–8 Barnikol-Watanabe S, <i>et al</i>. Biol Chem Hoppe Seyler 1994;375:497–512
Lung DNA Methylation in Chronic Obstructive Pulmonary Disease: Relationship with Smoking Status and Airflow Limitation Severity
Authors: Sandra Casas-Recasens, Guillaume Noell, Nuria Mendoza, Alejandra Lopez-Giraldo, Tamara Garcia, Angela Guirao, Alvar Agusti, Rosa Faner
Journal: American Journal of Respiratory and Critical Care Medicine (2020)
Distal pancreatectomy with multivisceral resection: A retrospective multicenter study – Case series
Authors: Jose M. Ramia, Juan V. del Río-Martín, Gerardo Blanco-Fernández, Miguel Cantalejo-Díaz, Fernando Rotellar-Sastre, Luis Sabater-Orti, Alberto Carabias-Hernandez, Alba Manuel-Vázquez, Pedro J. Hernández-Rivera, Isabel Jaén-Torrejimeno, Helga K. Kalviainen-Mejia, Sara Esteban-Gordillo, Elena Muñoz-Forner, Roberto De la Plaza, Texell Longoria-Dubocq, Noelia De Armas-Conde, Fernando Pardo-Sanchez, Marina Garcés-Albir, Mario Serradilla-Martín
Journal: International Journal of Surgery (2020)